AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 17, 2026, 1:34 PM ET Humacyte agreed to governance changes, including a disclosure committee lasting at least four years, to settle stockholder derivative cases in North Carolina and Delaware federal courts, pending preliminary court appr… AI-generated summary · Source: press report
Nasdaq: $HUMAVascular biotechnologyCommercial trauma indicationFunding and listing risk

HUMA Stock Hub: Humacyte News, Symvess Launch and Dialysis Filing

Humacyte’s central question is whether its trauma business can generate enough cash to sustain the company through a potential expansion into dialysis. Third-quarter product revenue reached $1.023 million, and Humacyte ended September with $64.523 million in cash and equivalents. The company planned to submit its dialysis application in November 2026, while its November 10 quarterly filing flagged substantial doubt about its ability to continue as a going concern. September-quarter filing · November 10 results and guidance.

Last updated: November 18, 2026Financial period: quarter ended September 30, 2026Currency: U.S. dollars
Full research report · PDF
Humacyte ($HUMA), research updated November 18, 2026
17 pages on Symvess adoption, dialysis access, September-quarter results, funding and risk. For personal use only: redistribution prohibited.
Get the report (PDF)
Next catalyst · company target
November 2026 · planned dialysis-access application

Humacyte targets November for submitting a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA). As of November 17, 2026, the company had yet to announce a submission or a specific day. November 10 company guidance · Company announcements.

The November 11 conference program lists presentations on November 18 and 19. See the dated calendar for the separate Nasdaq deadline.
Humacyte HUMA daily stock chart
Daily chart $HUMA. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

HUMA stock at a glance

Chart analysis · JC
Technical chart analysis of $HUMA with bull and bear scenarios on JC Just Charts.
Cash and equivalents · Sep 30
$64.523M
Symvess revenue · Q3 2026
$1.023M
Operating cash use · nine months
$62.139M
Avenue principal · Sep 30
$40.0M
Common shares · Nov 6
277.798M
Shares short · Oct 30
28.072M

Where Humacyte stands now

More hospitals had placed an order for Symvess by the end of September. The immediate financial test is whether those institutions reorder often enough to increase collections and absorb more production costs. A dialysis supplement would widen the opportunity if approved. Humacyte’s access to capital determines how much of that opportunity it can finance itself. Symvess adoption and economics · Cash and funding.

The main risk is a mismatch in timing. Humacyte incurs manufacturing, research and interest costs as it prepares its next regulatory submission. If commercial receipts arrive slowly, it may need fresh capital before it learns how the FDA will evaluate the dialysis application.

▲ The constructive case

Repeat trauma orders could help cover factory costs. Filing the supplement would give the dialysis program a path to formal review. The first disclosures to watch are completed submission, collections and lower cash use.

▼ The cautious case

New hospitals may order infrequently, even if the first purchase goes well. A lengthy review could prolong the need for outside capital. Costly financing could increase interest costs or dilute existing shares even as the clinical program advances.

Latest Humacyte news

Nov 17, 2026

Humacyte proposes governance reforms to settle stockholder derivative lawsuits

Humacyte agreed to corporate governance changes to settle stockholder derivative claims alleging that officers and directors caused it to misrepresent the safety of its lab-grown blood vessels, its cash reserves, and its compliance with manufacturing standards. The changes include a disclosure committee and would last at least four years. Shareholders sought preliminary court approval in the US District Court for the Middle District of North Carolina, and the deal would resolve derivative cases in North Carolina and Delaware federal courts. Not confirmed by a company release or filing at the time of writing; to be verified.

Nov 16, 2026

Humacyte Presents Long-Term Clinical Data on Low Atherosclerosis Susceptibility in ATEV

Humacyte presented an analysis of ATEV tissue from 52 patients across five clinical trials at the 2026 ISVTE-ISACB Joint Meeting in Miami. Minimal lipid deposition averaged 0.6% of tissue area, and none of the ATEVs showed evidence of vulnerable plaques. Over 95% of ATEV explants showed no or only a minor presence of early atherosclerosis markers, even after more than five years of implantation. Only 4.7% of ATEVs showed some atypical fatty streaks.

Nov 11, 2026

Barclays raises its Humacyte price target to $0.60

A secondary report says Barclays raised its price target from $0.50 to $0.60 and maintained Equal Weight. The target is the bank's assessment.

Nov 11, 2026

Humacyte's Acellular Tissue Engineered Vessel Featured in Five Presentations at VEITH 2026

Humacyte's acellular tissue engineered vessel (ATEV) will be featured in five presentations at the 53rd Annual VEITHsymposium, taking place November 17-21, 2026, at the New York Hilton Midtown in New York City. Four abstracts will be presented on Wednesday, November 18, including interim Phase 3 results in women receiving hemodialysis and integrated outcomes from three Phase 3 trials. A podium presentation on Thursday, November 19, will provide an update on clinical results with Symvess in military and civilian trauma settings.

Nov 10, 2026

Humacyte Reports Third Quarter 2026 Results, Symvess Revenue More Than Doubles

Symvess commercial sales reached $1.0 million in the third quarter, a 151% increase over the second quarter. October 2026 sales totaled $0.8 million. Humacyte plans to submit a supplemental Biologics License Application for the ATEV in dialysis access in November 2026. The net loss for the third quarter was $15.5 million.

Nov 9, 2026

Humacyte highlights first-in-human coronary bypass study at American Heart Association Scientific Sessions 2026

Humacyte has initiated the Phase 2a study of its investigational coronary tissue engineered vessel (CTEV) in patients undergoing coronary artery bypass grafting (CABG). The FDA accepted the Investigational New Drug (IND) application in July 2026, and the study will evaluate safety and efficacy in ten adult patients with coronary artery disease, with patency assessed two months after implant and follow-up for up to three years. The study is now open for enrollment, and the CTEV was highlighted in three presentations at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, Illinois.

HUMA catalyst calendar

  • October 2026–March 2027 — Window for a second Avenue draw of up to $12.5 million. Conditional · credit agreement disclosures
  • October 7, 2026 — Two directors reported option grants dated October 6. Filed · Coward Form 4 · Kuznik Form 4
  • October 15, 2026 — Humacyte updated hospital ordering figures. Reported · company release
  • October 22–23, 2026 — V012 interim results were presented at Kidney Week and summarized by the company. Presented · congress abstract
  • October 28, 2026 — Humacyte announced a new U.S. patent. Reported · company release
  • November 2, 2026 — The securities class action parties signed a settlement stipulation and the plaintiffs sought preliminary approval. Proposed settlement subject to court approval · Form 10-Q litigation note
  • November 9, 2026 — Humacyte announced the start of the Phase 2a coronary bypass study. Announced · company release
  • November 10, 2026 — September quarter results and Form 10-Q. Reported · results · quarterly filing
  • November 16, 2026 — Analysis of explanted tissue reported after a scientific meeting. Reported · company release
  • November 17, 2026 — Further terms of the proposed derivative settlement were reported. Secondary account · litigation and governance
  • November 18–19, 2026 — Five scheduled presentations at the VEITHsymposium in New York. Scheduled · November 11 program
  • November 2026 — Planned dialysis-access supplement. Company target · November 10 guidance
  • Fourth quarter of 2026 — Management expects Symvess sales to reach at least twice third-quarter sales. Company expectation · November 10 guidance
  • January 27, 2027 — Initial deadline to regain compliance with Nasdaq’s minimum bid rule. Disclosed listing deadline · listing notice

One approved indication and two investigational programs

Extremity trauma

Symvess is commercially available for a defined adult emergency indication. Read the commercial analysis.

Dialysis access

Phase 3 evidence informs a planned application to extend the label. Read the dialysis evidence.

Coronary bypass

The separate coronary vessel program has entered a first-in-human study. Read the clinical development analysis.

Humacyte deep dive: the full analysis

The chapters trace what would have to change in the clinic, at purchasing hospitals and on the balance sheet for Humacyte to become a sustainable commercial business. The Merlintrader Research Library collects our dated biotech stock research reports.

01 Three scenarios

Bull case

Symvess builds a base of repeat trauma customers over several quarters. Ordering broadens across hospitals, and the accounts that already carry the product replenish it more often. Higher unit turnover makes better use of the Durham facility and reduces the amount of unused capacity charged to each quarter. The company submits the dialysis supplement, the FDA accepts it for review, and the eventual approved label is broad enough to support a launch in patients whose access needs are hard to meet with a fistula. Both programs give Humacyte reasons to keep its commercial and clinical capabilities intact. Funding on workable terms lets it do so without cutting into the study follow-up or product support on which those plans depend.

In that case, repeat orders and lower cash use would matter as much as the filing announcement. Evidence of repeat demand makes the trauma franchise easier to model independently of a regulatory event. The approval case is stronger if the FDA accepts the benefit of earlier catheter independence in a defined population and the company can explain its management of access-related complications. The next evidence would come from the published review timetable, the approved label and, after a launch, actual customer orders. The underlying studies and cash position are discussed in dialysis evidence and cash and funding.

Base case

Trauma sales progress, with hospital adoption more predictable than the timing of individual procedures. The quarterly revenue line remains small compared with the payroll, facility and trial spending needed to support two indications. The dialysis application goes forward, but review and preparation for a potential launch consume cash during a period with limited options for financing. Management seeks capital as it works through the application. The financial outcome depends on the form of that capital, as well as its availability: a loan adds senior obligations, an equity offering changes the common share base, and a partner can take a share of later product economics.

The base case can hold even after favorable clinical or commercial news. Product revenue can grow while the facility remains underused. A hospital can place an initial order and wait several months to replenish it. FDA acceptance of the application can give the program a clearer timetable while leaving the scope of the label open. Look for sustained improvement in both sales and cost absorption before drawing conclusions about the trauma franchise’s ability to finance company-wide spending. See the income statement and credit terms.

Bear case

Trauma uptake levels off before the factory recovers enough fixed overhead, or cash collection lags sales. The agency requests further analyses, a narrower population or additional evidence from the dialysis program. Each outcome extends the period when the emergency indication carries the whole commercial business. If access to capital tightens during that interval, management may slow trial work or reduce commercial spending, risking the loss of some of the progress that made the application and launch feasible.

Common shareholders can face this outcome with a clinically useful product still on the market. A refinancing under pressure would have to account for the senior lender’s security and covenants. An equity transaction would add more shares to a base already increased by the spring and June financing. A Nasdaq compliance problem could complicate the timing of either route. These are separate mechanisms, set out in debt, financing and dilution and listing and trading liquidity.

What would falsify this reading

The current reading assumes that funding needs will remain material before the dialysis opportunity becomes commercially meaningful. It would need to change if recurring trauma orders began generating clearly better cash conversion while the company held down spending. One measure would be a sustained increase in collections alongside lower operating cash use. Another would be a quarter in which sales improve while inventory and receivables move in line with demand. The quarterly reports are more informative on this point than the count of hospitals ordering at least once.

The commercial assessment would weaken if the company reached its goal for new ordering hospitals while revenue growth or collections slowed. That combination would suggest small purchases per account, slow use or longer payment cycles, possibilities with different implications for the factory. A falling cost of goods line alongside wider adoption would support a different assessment than a falling cost of goods line during retrenchment. The company’s explanations of volume, capacity and inventory would determine which reading fits the results.

A partnership could also change the funding judgment. A signed agreement with usable upfront cash and funded work would affect the cash forecast at once. Payments contingent on future approval or volume would matter only if those milestones were reached. Economics ceded to the partner, including royalties or rights in a territory, would determine how much of eventual product revenue remains with Humacyte. Likewise, a dialysis label that covers fewer patients or carries material restrictions would change the commercial thesis even if formal approval arrived.

A further reason to revisit the case would be new trial evidence explaining the balance between earlier use and later access problems. A patient may benefit from fewer days with a catheter while still experiencing recurrent interventions. A study that only improves one part of that course leaves open where the costs and complications eventually land. A fair test of the proposed expansion must follow access use, safety and the need for additional procedures over time. Randomized V007 study · V012 interim announcement.

02 What Humacyte does

Humacyte develops implantable bioengineered human tissues. Its first commercial product is Symvess, an acellular tissue engineered vessel (ATEV). The FDA’s December 19, 2024, approval covers use as a conduit in adults with extremity arterial injuries for whom urgent restoration of blood flow is needed to avoid imminent limb loss and an autologous vein graft is infeasible. The narrow indication sets the demand boundary: the commercial opportunity depends on how often a qualifying case arises, whether a stocked unit is available and whether a treating surgeon chooses it. FDA indication and prescribing information.

Trauma and dialysis test different jobs for a vascular conduit. Trauma repair aims to restore flow in an emergency, when a surgeon may have few feasible options. Dialysis access needs to work repeatedly, for patients who may spend months or years using it. Availability matters in both settings. The evidence that guides selection, the frequency of use and the economics for the organization paying for care differ considerably. Humacyte’s manufacturing experience in one setting may help it prepare for another. Each indication still needs support for its own intended use.

The company reports one operating segment. Under its September-quarter accounting policies, domestic sales of Symvess make up product revenue. A small research contract produces a separate revenue line as services are performed. This reporting structure puts commercial uptake, research costs and financing effects into a single consolidated result. Tracking product revenue and cost of goods apart from consolidated net loss gives a clearer view of how the launch itself is progressing. Form 10-Q, accounting policies and management discussion.

President and Chief Executive Officer Laura E. Niklason and Chief Financial Officer, Chief Corporate Development Officer and Treasurer Dale A. Sander signed the November 10 filing. In the quarterly release, Chief Commercial Officer Jim Mercadante tied the company’s expectations to expanded hospital adoption and physician engagement. Those statements give investors specific operating claims to test in the next set of results. Quarter-end ordering accounts, repeat demand and realized sales will show whether expansion has moved beyond additional initial orders. Form 10-Q signatures · Company operating update.

03 The milestones that matter

The immediate regulatory milestone is the dialysis submission. Humacyte confirmed its timetable on August 24 after discussions with the FDA and reiterated it in its November results. Submission puts the data package in front of the agency. Acceptance for review, a decision timetable and a final decision would be separate disclosures. As of November 17, Humacyte had announced a November filing window without specifying a date. Even with a timetable, details such as the specific intended population, warnings or further evidence requirements would still affect the range of plausible commercial outcomes. August submission plan · November quarterly update.

The company announced on November 11 that the VEITHsymposium would include four November 18 abstracts and a November 19 podium talk. The program covers a case report on reconstruction in an infected field, the women’s dialysis trial, integrated durability and safety across three dialysis studies, explant histology and trauma use. The abstracts can help clinicians ask more precise questions about the studies and their applicability. November 11 presentation schedule.

Commercial progress will be measured over the entire fourth quarter. Humacyte’s November 10 announcement set an expectation of at least doubling the preceding quarter’s Symvess sales. The company reported about $0.8 million of sales in October, the first month of the quarter. The pace of urgent trauma use can vary across hospitals and months. The full quarter and the next explanation of product costs will show more than extrapolating October could. October sales and fourth-quarter expectation · Company announcements.

January’s Nasdaq deadline can arrive irrespective of progress with the FDA. Loan covenants and any new financing have separate timelines. Treating the next catalyst as a single switch obscures this sequence. Humacyte can submit a strong package and still have an immediate need for financing. It can also finance itself through review without improving how trauma sales absorb production costs. A sequence of observable changes is needed to validate the larger commercial case.

04 Symvess adoption and production economics

At September 30, Humacyte counted 49 hospitals that had ordered Symvess, up from 34 at June 30. The company expects at least 20 additional ordering hospitals in the second half of 2026. The third-quarter increase accounted for 15 of that target. Each new account gives Humacyte a chance to put Symvess on hand for eligible patients. The metric counts hospitals that placed an order. It cannot tell a reader directly how many cases qualified for treatment, how many units were implanted or how often the same hospital ordered again. The next sales report will be useful for gauging depth of adoption alongside the expanding footprint. Quarterly commercialization update · October company update.

The current label also brings clinical obligations. The FDA prescribing information carries a boxed warning about potentially life-threatening hemorrhage from a rupture in the graft or failure at the point where it joins a vessel. Hospitals that stock Symvess weigh those risks when assessing whether to use it in an eligible emergency. The existence of an inventory position is therefore different from proof of broad routine use. How centers qualify cases, manage follow-up and decide on reorders will determine whether adoption turns into a durable purchasing pattern. FDA label and safety information.

Humacyte announced on September 9 that the FDA authorized a shelf-life extension to 36 months. In a market driven by emergencies, a longer authorized life can give hospitals more time to use inventory they keep for infrequent cases. For Humacyte the test is whether reduced expiration pressure eventually makes stocking and manufacturing more efficient. Shelf life can support the distribution model. It cannot create eligible cases or predict which hospitals will use and replace the inventory. September 9 FDA authorization announcement.

The balance sheet carried $5.611 million of net inventory at September 30 against $13.589 million at December 31, 2025. The company recorded a $2.295 million inventory write-down during the first six months of 2026, with no additional inventory reserve expense recorded in the September quarter. Humacyte capitalizes certain manufacturing costs and records them when inventory is sold. Costs of unused manufacturing capacity can be expensed without being assigned to a shipped unit. Those accounting treatments mean a change in the inventory balance can reflect several effects, including investment in production, sales and reassessment of recoverable value. A lower balance alone says little about the strength of demand. Balance sheet, inventory note and results discussion.

September-quarter cost of goods sold exceeded total revenue, and the company connected about $0.8 million of cost of goods to unused capacity and royalties. Selling a higher volume could spread some fixed costs across more units. Royalties, by contrast, attach to commercial sales under the relevant agreements. As volumes change, the most telling evidence would be whether reported product revenue rises faster than the combined costs of output, unused capacity and royalties. The company’s economics require eventual improvement on this measure before the approved trauma franchise can contribute meaningfully to funding the broader business. September-quarter cost discussion.

05 What the dialysis evidence shows

Traditional arteriovenous fistulas connect an artery and vein so the vein can eventually support dialysis. Time to successful use matters because a patient who starts with a catheter can spend part of a year relying on it. The clinical case for Humacyte’s vessel is strongest where surgeons expect a fistula to be difficult to mature or use. To judge that case, keep functional patency, secondary patency and catheter-free days separate. Functional patency asks whether access is usable for dialysis. Secondary patency tracks maintained or restored access over time, allowing interventions. Catheter-free days reflect the course a patient actually experiences. A person can benefit on one measure while still facing problems on another.

The randomized V007 study assigned 242 participants to the investigational vessel or an autogenous fistula. In the published comparison, functional patency at six months was 81.3 percent with the engineered vessel and 66.4 percent with a fistula. The publication used an overall relative patency measure across the co-primary endpoints, reporting 1.17 with a 95 percent confidence interval of 1.04 to 1.31. The trial also reported more interventions overall among vessel recipients and similar access infection rates. Earlier usable access can be valuable even if maintaining it requires additional work. Both outcomes are relevant for clinical review and for assessing the economics of dialysis care. Peer-reviewed V007 results.

V012 directly studies women receiving hemodialysis. In the preplanned interim group of the first 80 participants with one year of follow-up, mean catheter-free time was about 220 days in the vessel arm and 129 days in the fistula arm. The difference was 91 days, with a 95 percent confidence interval of 40 to 142 days. The June company disclosure reported that its separate secondary patency comparison at 12 months was statistically inconclusive. The October congress abstract reported fewer infections across all access types in the vessel group. Study access infections were absent in both groups in that analysis. The broader infection count and the study access count describe different sets of events. The abstract reported more thrombosis and stenosis events in raw counts with the engineered vessel. After adjustment for time in use, the stenosis rate was lower with the engineered vessel. The denominators matter because the groups spent different amounts of time using the assigned access. October Kidney Week abstract · June interim disclosure · V012 study record.

The supplement is expected to use evidence from three Phase 3 studies. V006 compares the vessel with synthetic expanded polytetrafluoroethylene access, a different control from the fistula arm in V007 and V012. According to the 2025 annual report, V006 missed its prespecified primary efficacy endpoint on secondary patency. The 12-month analysis showed noninferiority, while the 24-month analysis did not. The company also reported a lower rate of conduit infection. Combining perspectives can make the evidence more useful, provided the comparison being made stays clear. An effect against one option in one population does not give the size of the effect versus every access option. The eventual regulatory label and supporting materials would show which evidence the FDA found relevant to the intended patients. V006 study record · 2025 Form 10-K, V006 results · Company filing plan.

In a November 16 release, Humacyte described a separate analysis of explanted tissue from 52 patients across five studies. Samples came from vessels implanted for periods ranging from less than a week to more than five years. The company reported lipid deposits averaging 0.6 percent of sampled tissue area and no vulnerable plaques in the samples. That analysis addresses what researchers saw in recovered tissue. The sample selection and absence of a reported comparator limit what it can say about how often clinical events occur in all implanted patients. It cannot substitute for a study comparing the frequency of access complications, or establish outcomes for the coronary program. November 16 explant analysis.

06 Coronary bypass, intellectual property and rights

Coronary artery bypass grafting (CABG) uses a conduit to reroute blood around blocked coronary arteries. In July 2026 Humacyte announced that the FDA had accepted its investigational new drug application for a study of a coronary tissue engineered vessel (CTEV) for bypass. On November 9 it announced that the first-in-human Phase 2a study was open for enrollment and that it expected screening to begin. Its November 10 results release identified activation of the first site as the step that started the study. The protocol plans to enroll ten adults, assess vessel patency at two months and follow participants for as long as three years. As of November 17, Humacyte had yet to announce treatment of the first patient. November 9 study announcement · November 10 results release · Coronary study registration.

The presentations at the November 7–8 American Heart Association Scientific Sessions included the clinical study design and preclinical work. Those presentations explain the reason for testing the vessel in people. Meaningful human evidence would come from following the enrolled cohort and understanding the nature, timing and clinical consequences of any loss of patency or other adverse events. A small initial study can provide information on feasibility and safety. With ten planned participants, the result would leave considerable uncertainty about performance in a much larger or less selected population. Scientific meeting and clinical study announcement.

Peripheral artery disease is another potential use for the engineered vessel. Humacyte has conducted earlier studies in this area, including trials of limb bypass, and the September filing includes potential additional work in its discussion of future funding needs. The 2025 annual report also describes research in pediatric heart surgery and type 1 diabetes. The next dated regulatory milestone for a new indication is the planned dialysis supplement. 2025 Form 10-K, pipeline · September filing, future funding needs.

In an October 28 release, Humacyte announced U.S. patent 12,742,144 and projected protection until 2043 for claims covered by that patent. Specific claims, rather than the company’s entire product category, determine the legal scope. The grant supports a longer intellectual-property horizon for the covered subject matter. It does not advance any clinical trial, broaden the FDA label or guarantee an exclusive position across all engineered conduits. October 28 patent announcement.

The April 21, 2026 amendment to the Fresenius Medical Care distribution agreement restored worldwide development, commercialization and regulatory rights for the covered product to Humacyte. Under the amended terms, U.S. net sales remain subject to royalties ranging from mid-single digits to low double digits. For sales outside the United States, royalties are in the low single digits after a two-year royalty-free period following launch in each applicable country. Fresenius retains an obligation to support adoption as a standard of care in hemodialysis when clinical evidence and health economics analyses support that use. Humacyte has more control over the timing and structure of a prospective international launch, together with more responsibility for securing regulatory access and executing it. Form 10-Q, related-party transactions.

07 September-quarter results

Product sales accounted for almost all third-quarter revenue. Contract revenue had fallen to $5,000 as a research project wound down. The table preserves the distinction between product revenue and total revenue that can disappear when both figures round to $1.0 million in a release. Figures are in thousands of U.S. dollars except per-share amounts and weighted-average shares. Parentheses indicate losses. September-quarter consolidated statements of operations.

Reported lineQ3 2026Q3 2025Nine months 2026Nine months 2025
Product revenue, net1,0237031,922950
Contract revenue5507621
Total revenue1,0287531,9291,571
Cost of goods sold1,4292604,698620
Research and development14,10417,27351,71054,697
General and administrative9,0147,61024,97123,555
Loss from operations(23,519)(24,390)(79,450)(77,301)
Other income, net7,9816,8809,49161,272
Net and comprehensive loss(15,538)(17,510)(69,959)(16,029)
Loss per share, basic and diluted(0.06)(0.11)(0.30)(0.11)
Weighted-average shares, basic and diluted277,798,105158,313,290236,901,920148,514,044

The quarter’s loss became smaller year over year, while the nine-month loss became materially larger. Revaluations help explain why those signals point in different directions. The earlier nine-month period included much larger gains from remeasuring the contingent earnout and derivatives. In Q3 2026 those categories still contributed $3.387 million and $6.363 million respectively. The revaluations change earnings without producing operating receipts. Operating losses show a much narrower change between the two nine-month periods and a clearer picture of the continuing expense burden. Income statement and fair value notes.

Research and development remained the largest operating cost in the September quarter. The company reported lower spending in that category than the prior year while general and administrative expense rose. The November 10 release linked part of the administrative increase to net expense associated with litigation reserves and related legal costs. Product sales, factory cost, research spending and litigation therefore moved through different lines of the statement. Using only the quarterly net loss to judge whether Symvess is approaching sustainable economics would mix several changes unrelated to the number of units hospitals ordered. Quarterly results commentary · Legal exposures and proposed settlements.

The loss per share also compares periods with significantly different weighted-average share counts. The quarter’s average is equal to the cover-page count in the November filing, while the nine-month average is lower because the financing shares entered the base during the year. A reader evaluating dilution needs the point-in-time share count. A reader comparing reported loss per share needs the stated average for the relevant period. Share count and financing · Form 10-Q, loss per share and stockholders’ equity.

08 Cash and the cost of reaching the next milestone

On September 30 the company had $64.523 million in cash and equivalents, against $50.497 million at December 31, 2025. The September cash flow statement shows $64.876 million including restricted amounts. Total restricted cash was $353,000. Of that amount, $144,000 was included in other current assets and $209,000 was listed as restricted cash outside current assets. The balance sheet also carried $811,000 of trade receivables. A separate insurance recovery asset belongs to the legal matters described below. Those assets have different availability and collection terms from cash in the bank. Balance sheet and cash reconciliation.

Operating activities used $62.139 million over the first nine months of 2026, down from $78.918 million over the same months a year earlier. The company reported $15.0 million of operating cash use for the September quarter alone, versus $23.9 million a year earlier. The nine-month cash flow benefited from a smaller buildup of inventory alongside fewer production runs. Lower operating cash use is welcome, but a change in working capital can reverse if production grows again or if customers take longer to pay. Receipts from commercial sales, purchase commitments and the frequency of production runs matter for what comes next. Nine-month cash flows and management discussion · Third-quarter cash use.

Financing activities supplied a net $76.444 million in nine months, which exceeded the combined operating and investing outflows. Investing used $279,000, chiefly for property and equipment. Cash and restricted cash therefore ended the period above the previous year-end balance despite substantial operating consumption. Cash can increase between reporting dates even when operations still depend on outside funding. The cash flow statement shows which of those forces was larger over the reporting period. Nine-month cash flow statement.

Merlintrader calculation: dividing unrestricted cash at September 30 by average monthly operating use in the first nine months produces about 9.3 months of coverage at that historical pace. Applying the isolated September-quarter rate gives about 12.9 months using the rounded quarterly cash-use figure. The calculations start at September 30 and leave out post-quarter flows, new financing, capital expenditures and debt or lease principal. A lender covenant, an unusual settlement payment or changes in trial and launch spending could matter before an arithmetic cash exhaustion point. The range shows how much the estimate depends on the spending period. Cash and nine-month operating flow inputs · Quarterly cash use input.

The November 10 filing says timely commercial cash flows or new capital are needed and concludes there is substantial doubt about continuation as a going concern. In May management implemented a reduction plan covering approximately 45 employees, deferred planned hires and reduced other operating costs. Management described possible funding through equity, debt, restructuring or collaborations and said it could reduce or delay investments, research or commercialization if funding fails to materialize. Cuts can conserve near-term cash. Their long-term cost depends on which work is slowed and whether the business can restore capacity when necessary. Going-concern assessment and commitments.

09 Avenue debt and committed spending

Avenue’s December 2025 agreement provided a senior secured term facility of up to $77.5 million. The company drew $40 million at closing and remained at that nominal principal on September 30, 2026. Amortized carrying value was $36.803 million after accounting for debt discounts and issuance costs. Lenders have security over substantially all assets of the company and certain subsidiaries. That security gives the lender a stronger position if liquidity deteriorates and matters to a prospective buyer of newly issued debt or a partner proposing to take rights over assets. Form 10-Q, Note 6.

Additional tranches of up to $12.5 million and $25 million depend on specified revenue, regulatory and liquidity conditions as well as lender discretion. The disclosed terms place the second window between October 2026 and March 2027 and the third between July 2027 and June 2028. An available application window is one step. Funding depends on meeting the agreement’s conditions. The third tranche’s regulatory timing also shows why the maximum facility amount cannot be used as a substitute for liquid assets during the early part of a review. Avenue facility terms · September facility balances.

The interest rate is the higher of 11.50 percent and the prime rate plus 4.50 percentage points. Interest-only payments began in January 2026. Scheduled principal repayment starts December 1, 2027, moving to December 1, 2028 if the second tranche is funded. The loan matures December 1, 2029 and carries a $2.4 million final fee. Extending the interest-only period would defer principal, and drawing additional capital would increase the amount on which financing costs accrue. The company’s cash burden will also depend on the path of the variable reference rate. Interest, maturity and final payment fee.

Humacyte used much of the original draw to end its earlier revenue interest financing. The old arrangement was terminated in December 2025 in exchange for $38 million of cash and 5,725,190 common shares. The comparison matters because Avenue’s interest, collateral and conversion terms now drive the credit analysis. The prior terms do not describe current obligations under Avenue. Lease liabilities at September 30 were $609,000 current and $29.070 million long term. The company also disclosed $19.5 million of non-cancelable purchase commitments, principally for research and development supplies and services. Those claims on cash sit alongside the cost of running trials and the effort to commercialize Symvess. Notes 5 and 6 and material cash requirements.

10 Equity raised and shares outstanding

Humacyte had 277,798,105 common shares outstanding on the November 6 filing-cover date, the same as on the September 30 balance sheet. The December 31, 2025 balance was 193,000,611. The authorization rose from 350 million to 550 million common shares over that period. The outstanding count measures shares already issued. The authorized count is the charter limit, including shares that could subsequently be issued or reserved. Neither the higher authorization nor an unused reserve represents proceeds in the bank. Cover page, balance sheet and stockholders’ equity note.

The March registered direct offering comprised 25 million shares at the contractual price of $0.80 per share. The nine-month cash flow statement reports $18.319 million net after placement agent fees for registered direct offerings. In June, the public offering raised another approximately $53.8 million after underwriting and expenses. The firm sale of 47,619,048 shares closed June 12. An additional 7,142,857 underwriter-option shares closed June 16 at the same $1.05 offering price. Those transactions made a significant contribution to June liquidity. The September balance incorporates the cash raised and the operating activity that followed. Offerings in Notes 1 and 7 and nine-month cash flows.

Humacyte sold 4,018,497 shares under the TD Cowen at-the-market (ATM) agreement for about $4.6 million in net proceeds in the first quarter. The company suspended and terminated the relevant sales prospectus on March 19. The underlying agreement remained in effect, with further sales requiring appropriate prospectus or registration coverage. The company reported no sales after the first quarter through September 30. It would take a new filing or transaction to establish when cash from a renewed program was available and on what terms. Form 10-Q, TD Cowen ATM facility.

The Lincoln Park equity line expired October 1 with $47.5 million of unused capacity. The company sold no shares under it during the first nine months of 2026. Accordingly, September’s unused capacity ceased to be an option immediately after quarter-end. This distinction matters because equity lines can appear in liquidity discussions for a long period even if their usefulness changes substantially. A reader evaluating current funding should look at proceeds already received, conditions for available capital and any replacement arrangement separately. Note 7 and discussion of liquidity sources.

The quantity of shares a prospective offering could add depends on its size, terms and the mix of securities. A structure with warrants could deliver common stock and further contingent claims on the share base at the same time. A debt refinancing may leave the near-term common count intact while increasing interest or adding conversion rights. A distribution or licensing deal may leave the count unchanged while redirecting part of future sales. The relevant question for a common shareholder is what remains after paying for the extra time each route buys.

11 Warrants, employee awards and contingent shares

The September 30 warrant schedule reports 37,598,053 common stock warrants outstanding. The largest group was 28,436,018 from the October 2025 registered direct offering, with a contractual exercise price of $2.11. The two 2024 registered-direct groups consisted of 2,840,910 October warrants at $5.28 and 1,404,494 November warrants at $5.34. The schedule also includes 411,006 legacy warrants at $10.28, 240,000 other warrants and the Avenue warrants. The 2021 public and private placement warrants expired without exercise on August 26, 2026 and are excluded from the September total. Form 10-Q, Note 7 warrant schedule and terms.

The filing lists 4,265,625 Avenue warrants in the outstanding schedule. Their contractual exercise price reset to $0.80 after the March offering. The agreement provides about $3.4 million of base exercise value and roughly $1.6 million more contingent on funding the third loan tranche. In the broader reserve table the company shows 39,629,303 shares reserved for warrants, including the additional contingent component. Those tables measure different categories. Cashless exercise is possible under the loan warrant terms, so it would be unsafe to treat every potential exercise as future cash proceeds. Loan warrant and equity reserve disclosures.

The loan also gives lenders a conditional right to convert up to $2.5 million of principal at $1.04 per share after the March reset. Humacyte reserved 2,403,846 shares for the feature, with none issued upon conversion as of September 30. A separate contingent earnout has 15 million reserved shares. Both can affect the future share base if their conditions are met. They confer different rights and are economically distinct from the warrants outstanding. The September carrying values of derivative and earnout liabilities represent financial statement measurements rather than immediate principal repayments. Note 7, conversion feature and contingent earnout.

At September 30 stock plans had 16,365,498 options outstanding with a weighted-average exercise price of $4.06. Of those, 9,202,714 were vested and exercisable. There were 990,485 restricted stock units (RSUs) outstanding, separate from the option schedule. The company reported 10,198,526 options available for future issuance under its stock plans. Shares available for future grant are a different category from existing awards. Vesting, expiry and exercises determine how many awards ultimately translate into issued shares. Notes 7 and 8, reserves and stock-based compensation.

Two Forms 4 filed October 7 reported that directors Scott D. Coward and Paul Brian Kuznik each received a grant of 125,000 options on October 6 at an exercise price of $0.478. The filings use transaction code A for grants. The awards came after the September 30 balance sheet date, so the September option table and the October transactions belong to different dates. Coward Form 4 · Kuznik Form 4.

12 Ownership, trading liquidity and Nasdaq status

In the August 18 amended Schedule 13D, Fresenius Medical Care Holdings and its parent reported the same 13,603,235 shares, or 4.9 percent of the outstanding voting stock on the stated August share base. Fresenius reported sales between August 10 and August 17 under a previously established trading plan and said it had ceased to own more than five percent on August 17. The shared holding is one block. A dated ownership filing describes the position at the stated date. The distribution and royalty relationship comes from a separate contract and remains relevant even if the ownership stake changes. August 18 Schedule 13D amendment · Distribution agreement analysis.

Other ownership filings also need to be read at their own dates and with attention to who shares voting or dispositive power. BlackRock’s July 28 Schedule 13G amendment reported 4,092,430 shares, or 1.5 percent, for the reporting entities as of June 30. A June Davidson Kempner filing identifies power through overlapping investment vehicles. Adding the managers’ holdings to positions attributed to those same vehicles can count the same shares more than once. The April proxy’s executive and director totals predate the June issuance and therefore use an earlier ownership base. BlackRock Schedule 13G amendment · Davidson Kempner Schedule 13G · 2026 proxy statement.

Exchange short interest for the October 30 settlement was 28,071,815 shares against average daily volume of 3,906,141 shares in the exchange report, giving 7.19 days to cover. At the October 15 settlement the exchange reported 30,251,083 shares short and 3.66 days to cover. Fewer shares were short at the later snapshot, while average volume fell enough to make the position larger relative to trading activity. This ratio reflects the dated volume used in the report. Trading conditions can shift between Nasdaq reporting dates. Nasdaq settlement history.

Nasdaq notified Humacyte on July 31 that its common stock did not meet the $1.00 minimum closing-bid requirement. The initial period to regain compliance runs to January 27, 2027. The notice had no immediate effect on the listing; the September-quarter filing continued to describe common-share trading on the Nasdaq Global Select Market. Any additional period depends on the exchange’s criteria. The August Form 25 concerned the public warrants that expired and addressed a different listed security. July 31 listing disclosure · September-quarter risk factors and warrant note.

13 Litigation, governance and the investment case

In the securities class action in the U.S. District Court for the Middle District of North Carolina, No. 1:24-cv-00954, a March 31, 2026 order allowed claims related to alleged product-safety misstatements or omissions to proceed at the pleading stage. It dismissed several other sets of claims without prejudice. The parties signed a proposed $9 million settlement on November 2 and plaintiffs sought preliminary approval. The procedural ruling concerns what may proceed; the settlement concerns how the parties propose to resolve the case. Court approval remains a condition. March 31 court order · Form 10-Q litigation note.

The derivative actions have separate terms. Humacyte’s Form 10-Q describes an agreement in principle reached in September for governance changes and a proposed $750,000 payment of plaintiffs’ attorneys’ fees. It also reports a November 2 request for preliminary approval. A November 17 secondary report says shareholders made a November 16 request in the consolidated derivative matter and that the proposed measures include a disclosure committee and governance changes lasting at least four years. Those additional details remain unconfirmed by a primary filing. Readers can verify the account in the linked report. Quarterly filing, Note 10 · Secondary report (minor site).

The September balance sheet shows a $9.750 million litigation settlement liability and a separate $9.119 million insurance recovery asset. The filing describes the recovery as probable under the relevant directors’ and officers’ coverage. Recognizing a recovery asset reflects the accounting assessment at the reporting date. Payments and reimbursements can occur on different dates and put different demands on near-term liquidity. The general and administrative line captures the net accounting effects reflected in earnings, while cash flow depends on when the parties and carriers settle their respective obligations. September balance sheet and litigation disclosures.

Humacyte’s financial prospects turn on how much of the dialysis opportunity it can retain while funding its commercial launch. The emergency indication has real product revenue, purchasing centers and actual production costs to observe. The dialysis program has randomized evidence and a planned regulatory milestone, with future commercial economics dependent on the label, timing and launch. The equity claim ties them together through the financing needed in between. The plausible value of a second franchise depends on both the operating business it could become and the amount of that future business existing shareholders would still own.

Merlintrader Health Score · $HUMA

2.20out of 5
Balance sheet and runway · 30%1.5

The September 30 balance held $64.523 million of cash and equivalents, with $62.139 million used in nine months of operations and $40 million of drawn secured principal. The November 10 filing reported substantial doubt about Humacyte’s ability to continue as a going concern. Form 10-Q.

Catalyst · 30%3.5

Humacyte has a defined November submission window and Phase 3 evidence on dialysis access. As of November 17, Humacyte had yet to announce submission. FDA acceptance and any label expansion depend on subsequent agency decisions. Company guidance · V012 congress abstract.

Dilution · 20%1.0

There were 277,798,105 shares outstanding on November 6. September’s 37,598,053 outstanding warrants, existing awards and possible financing create material dilution risk. Share count and Notes 7–8.

Liquidity · 10%2.5

Nasdaq reported 3.906 million shares of average daily volume and 7.19 days to cover at the October 30 settlement. The January 27 common-stock compliance deadline weighs on the score. Nasdaq settlement report · Listing notice.

Execution · 10%2.5

Symvess product revenue was $1.023 million in the September quarter and more hospitals placed orders. Unused manufacturing capacity still burdened product economics. September financials · Company operating update.

Assessed November 18, 2026. Merlintrader calculation: 1.5 × 30% + 3.5 × 30% + 1.0 × 20% + 2.5 × 10% + 2.5 × 10% = 2.20 out of 5.

HUMA red flags

  • Unused factory capacity. Hospital reach can grow while inventory economics remain weak. Watch the cost and collection trends in Symvess adoption.
  • Funding tied to conditions. Avenue’s undrawn tranches and the expired Lincoln Park line affect financing flexibility on different timelines. See debt and equity.
  • Different signals within the dialysis evidence. Earlier use and time free of a catheter must be weighed alongside later patency, complications and interventions. See the trial evidence.
  • Listing and trading liquidity. The compliance deadline can affect financing discussions even as work toward the dialysis supplement proceeds. See Nasdaq status.

HUMA Stock FAQ: Humacyte Questions Answered

When is the next HUMA catalyst?

As of November 17, 2026, Humacyte was targeting November for submission of its dialysis-access supplement to the FDA. The company had announced no submission day. If Humacyte submits the supplement, FDA acceptance for review would be a separate milestone. November 10 company guidance · Company announcements.

Is Humacyte’s Symvess FDA approved?

Yes. The FDA approved Symvess on December 19, 2024, for certain adult extremity arterial injuries requiring urgent revascularization to avoid imminent limb loss when an autologous vein graft is infeasible. Dialysis access was still investigational as of November 17, 2026. FDA indication and approval · Dialysis program update.

How much cash does Humacyte have, and how long could it last?

Humacyte reported $64.523 million in cash and equivalents at September 30, 2026. The November 10 filing gives no cash exhaustion date and reports substantial doubt about Humacyte’s ability to continue as a going concern without timely commercial cash flows or fresh capital. The cash and funding chapter shows how operating use changed. Form 10-Q.

Is HUMA stock exposed to dilution?

Yes. As of September 30, 2026, Humacyte reported outstanding warrants, options and restricted stock units that can affect its future share count. The cover of the November filing reports 277,798,105 outstanding common shares as of November 6, 2026. Form 10-Q cover and Notes 7–8.

When does Humacyte report earnings?

As of November 17, 2026, Humacyte had not announced its next earnings date. The company’s latest results, reported November 10, covered the quarter ended September 30, 2026. See September-quarter results for the financial statements. Quarterly release · Company events.

What does Humacyte do?

As of November 2026, Humacyte develops engineered human tissues for implantation and sells Symvess for a defined form of urgent arterial repair. It is also developing vessels for dialysis access and coronary bypass. Each intended use has its own evidence and regulatory path.

Sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $HUMA or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, court records and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Biotechnology companies face clinical, regulatory and commercial risk. Safety findings, delays in approval, limited use of an approved therapy, production costs and the need for additional financing can lead to investment losses. Humacyte disclosed substantial doubt about its ability to continue as a going concern in its September 2026 Form 10-Q. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.